Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 123 clinical trials
Featured trial
TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

  • 300 views
  • 08 Nov, 2020
  • 1 location
Very Low Carbohydrate Diets and Glucagon Response in T1DM

controversial, because of their restrictive nature and theoretical concerns regarding growth, ketoacidosis and hypoglycemia risks and efficiency of glucagon treatment for hypoglycemia. Glucagon is used as a

  • 0 views
  • 21 Feb, 2022
  • 1 location
Effects of Glucagon-Like Peptide-1 Analogs on Sexuality (DESIRE)

This placebo-controlled, double-blind crossover study is to evaluate the GLP-1 analogue dulaglutide regarding changes in sexuality, the mood and the reproductive axis in healthy men.

Accepts healthy volunteers
  • 0 views
  • 14 Mar, 2022
  • 1 location
Glucagon-like Peptide-1 in Type 1 Diabetes

The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.

  • 0 views
  • 27 Apr, 2022
  • 1 location
Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

REMD-477 (Volagidemab) is a human anti-glucagon receptor antibody. Its proposed mechanism of action in controlling hyperglycemia is by blocking glucagon receptor (GCGR) signaling. In this way

  • 1 views
  • 25 Nov, 2021
  • 1 location
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

. The purpose of this research study is to evaluate the role of GLP1R in the response to elevated glucagon concentrations.

Accepts healthy volunteers
  • 32 views
  • 23 Mar, 2022
  • 1 location
Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism (Glucagon)

studied. Study subjects will receive a continuous glucagon infusion for 12 hours. Following glucagon infusion, subjects will receive prime-continuous tracer infusions for additional 4 hours to measure

Accepts healthy volunteers
  • 3 views
  • 01 Mar, 2022
  • 2 locations
Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

The current study is designed to test the feasibility of the a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus

  • 0 views
  • 15 Feb, 2022
  • 1 location
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients

Glucagon-like peptide-1 receptor (GLP-1R)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect insulinoma, like the widely studied

  • 1 views
  • 12 Sep, 2021
  • 1 location
16-week Flexible vs. 8-week Semaglutide Titration

Semaglutide is a Glucagon Like Peptide 1 (GLP-1) receptor agonist recently approved in Israel to improve glycemic control in patients with type 2 diabetes mellitus. Semaglutide is currently

  • 0 views
  • 25 Jan, 2021
  • 1 location